<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849182</url>
  </required_header>
  <id_info>
    <org_study_id>VERT-2017-001</org_study_id>
    <nct_id>NCT04849182</nct_id>
  </id_info>
  <brief_title>Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV</brief_title>
  <official_title>Randomized, 3-arm Controlled Clinical Trial, Designed to Evaluate the Effectiveness of Supplementation With Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV (Benign Paroxysmal Positional Vertigo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria Locale di Matera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Sanitaria Locale di Matera</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, 3-arm controlled clinical study, to evaluate the effectiveness of supplementation&#xD;
      with Vertistop® D (food supplement containing alpha-lipoic acid at modified release,&#xD;
      Carnosine and Zinc, Vitamin D and Vitamins B) and Vertistop® L (food supplement containing&#xD;
      fast releasing alpha-lipoic acid, Carnosine, Zinc and Curcumin) in preventing recurrence of&#xD;
      high-recurrence BPPV (Benign Paroxysmal Positional Vertigo)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign paroxysmal positional vertigo (BPPV) is the most common type of vertigo detectable in&#xD;
      otoneurological clinical practice. It is characterized by violent, short and relapsing&#xD;
      vertiginous crises that arise when the patient assumes certain positions of the head in the&#xD;
      space and is accompanied by a usually &quot;typical&quot; paroxysmal positional nystagmus. In most&#xD;
      cases we cannot trace the exact causal agent, so we mainly identify two forms: primitive&#xD;
      forms and secondary forms. BPPV therapy is essentially physical, and it is based on specific&#xD;
      maneuvers which make the otoconial mass come out of the semicircular canal. Recent studies&#xD;
      showed the existence of a seasonal trend of BPPV related to fluctuations in Vitamin D levels.&#xD;
      Based on these considerations this clinical trial was designed in order to evaluate the&#xD;
      possible efficacy of the administration of Vitamin D (Vertistop® D) in preventing recurrence&#xD;
      of BPPV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Actual">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of BPPV recurrences in patients supplemented with Vertistop D</measure>
    <time_frame>0, 6 months</time_frame>
    <description>Change in the number of BPPV recurrences associated with the increase or normalization of Vitamin D serum levels after supplementation with Vertistop D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of BPPV recurrences in patients supplemented with Vertistop-L</measure>
    <time_frame>0, 6 months</time_frame>
    <description>This parameter is defined as the difference in the number of BPPV recurrences observed in the period between the baseline visit and the final visit (after 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in Dizziness Handicap Inventory (DHI) values</measure>
    <time_frame>0, 6 months</time_frame>
    <description>This parameter is defined as the mean difference in the DHI values between the baseline visit and the final visit (after 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in the Visual Numeric Scale (VNS) values</measure>
    <time_frame>0, 6 months</time_frame>
    <description>This parameter is defined as the mean difference in the VNS values between the baseline visit and the final visit (after 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in the Visual Analogue Scale (VAS) values</measure>
    <time_frame>0, 6 months</time_frame>
    <description>This parameter is defined as the mean difference in the VAS values between the baseline visit and the final visit (after 6 months)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2, 4, 6 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Benign Paroxysmal Positional Vertigo (BPPV)</condition>
  <arm_group>
    <arm_group_label>Vertistop D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with deficiency (&lt;20 ng/mL, &lt;50 nmol/L) or insufficiency (20-30 ng/mL, 50-75 nmol/L) of Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vertistop L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with normal vitamin D levels (&gt;30 ng/mL, &gt;75 nmol/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients meeting the inclusion criteria with normal levels of vitamin D (&gt;30 ng/mL, &gt;75 nmol/L)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vertistop D</intervention_name>
    <description>Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals</description>
    <arm_group_label>Vertistop D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vertistop L</intervention_name>
    <description>Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)</description>
    <arm_group_label>Vertistop L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary BPPV;&#xD;
&#xD;
          -  Patients having BPPV of CSP or CSL (geo or apo, single or multi channel);&#xD;
&#xD;
          -  Patients with recurrent BPPV, defined as two or more episodes over the last six&#xD;
             months, or three or more episodes in the last 12 months;&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age;&#xD;
&#xD;
          -  Secondary BPPV;&#xD;
&#xD;
          -  Vitamin D levels greater than 100 ng/mL (&gt;250 nmol/L);&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policoro Hospital &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Matera</city>
        <zip>75100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Sanitaria Locale di Matera</investigator_affiliation>
    <investigator_full_name>Prof. Giacinto Asprella Libonati</investigator_full_name>
    <investigator_title>Medical Executive</investigator_title>
  </responsible_party>
  <keyword>BPPV</keyword>
  <keyword>Vertistop</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Alpha-lipoic acid</keyword>
  <keyword>Zinc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Benign Paroxysmal Positional Vertigo</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

